The emerging role of the ubiquitin proteasome in pulmonary biology and disease

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 5, 2013, Pages 530-537

  Weathington, Nathaniel M ^a   Sznajder, Jacob I ^b   Mallampalli, Rama K ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Drug development; E3 ligase; Proteasome; Pulmonary disease; Ubiquitin

Indexed keywords

BORTEZOMIB; CARFILZOMIB; F BOX PROTEIN; INTERLEUKIN 33; LUNG SURFACTANT; PEVONEDISTAT; PROTEASOME; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC ASTHMA; CELL FUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; ENZYME DEGRADATION; FLUID BALANCE; HUMAN; ION TRANSPORT; LUNG CANCER; LUNG DISEASE; LUNG EDEMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OXYGEN SENSING; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; PULMONARY VASCULAR DISEASE; RESPIRATORY TRACT INFLAMMATION; REVIEW;

F-BOX PROTEINS; HUMANS; LUNG; LUNG DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84883512048     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201304-0754PP     Document Type: Review

References (72)

1. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005;6:79-87.
2. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82:373-428.
3. Jiang YH, Beaudet AL. Human disorders of ubiquitination and proteasomal degradation. Curr Opin Pediatr 2004;16:419-426.
4. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction- Alzheimer's disease of the heart? N Engl J Med 2013;368:455-464.
5. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003;40:427-446.
6. Bouchecareilh M, Balch WE. Proteostasis: A new therapeutic paradigm for pulmonary disease. Proc Am Thorac Soc 2011;8:189-195.
7. Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin- proteasome system. Nat RevMol Cell Biol 2008;9:679-690.
8. Kirisako T, Kamei K, Murata S, Kato M, Fukumoto H, Kanie M, Sano S, Tokunaga F, Tanaka K, Iwai K. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 2006;25:4877-4887.
9. MetzgerMB, Hristova VA, Weissman AM. HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci 2012;125:531-537.
10. Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 2004;5:739-751.
11. Jin J, Cardozo T, Lovering RC, Elledge SJ, PaganoM, Harper JW. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 2004;18:2573-2580.
12. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, MukherjiM, Schofield CJ, et al. Targeting of HIF-a to the von Hippel-Lindau ubiquitylation complex by O2- regulated prolyl hydroxylation. Science 2001;292:468-472.
13. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012;148:399-408.
14. Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, Colbert RA. Immunoproteasome assembly: cooperative incorporation of interferon g (IFN-g)-inducible subunits. J Exp Med 1998;187:97-104.
15. Sixt SU, Peters J. Extracellular alveolar proteasome: possible role in lung injury and repair. Proc Am Thorac Soc 2010;7:91-96.
16. Lomma M, Dervins-Ravault D, Rolando M, Nora T, Newton HJ, Sansom FM, Sahr T, Gomez-Valero L, Jules M, Hartland EL, et al. The Legionella pneumophila F-box protein Lpp2082 (AnkB) modulates ubiquitination of the host protein parvin B and promotes intracellular replication. Cell Microbiol 2010;12:1272-1291.
17. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 2001; 15:3104-3117.
18. Bomberger JM, Ye S, Maceachran DP, Koeppen K, Barnaby RL, O'Toole GA, Stanton BA. A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog 2011;7: e1001325.
19. Ma XZ, Bartczak A, Zhang J, Khattar R, Chen L, Liu MF, Edwards A, Levy G, McGilvray ID. Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome. J Virol 2010;84:12419-12428.
20. Younger JM, Chen L, Ren HY, Rosser MF, Turnbull EL, Fan CY, Patterson C, Cyr DM. Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell 2006;126:571-582.
21. Benharouga M, Haardt M, Kartner N, Lukacs GL. COOH-terminal truncations promote proteasome-dependent degradation of mature cystic fibrosis transmembrane conductance regulator from post-Golgi compartments. J Cell Biol 2001;153:957-970.
22. Ye S, Cihil K, Stolz DB, Pilewski JM, Stanton BA, Swiatecka-Urban A. c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells. J Biol Chem 2010;285:27008-27018.
23. Olivera WG, Ridge KM, Sznajder JI. Lung liquid clearance and Na, KATPase during acute hyperoxia and recovery in rats. Am J Respir Crit Care Med 1995;152:1229-1234.
24. Zhou G, Dada LA, Chandel NS, Iwai K, Lecuona E, Ciechanover A, Sznajder JI. Hypoxia-mediated Na-K-ATPase degradation requires von Hippel Lindau protein. FASEB J 2008;22:1335-1342.
25. Verma IM. NF-kB regulation in the immune system. Nat Rev Immunol 2002;2:725-734.
26. Mercurio F, Manning AM. Multiple signals converging on NF-kB. Curr Opin Cell Biol 1999;11:226-232.
27. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, Tanaka K, Nakano H, Iwai K. SHARPIN is a component of the NFkB- activating linear ubiquitin chain assembly complex. Nature 2011; 471:633-636.
28. Rieser E, Cordier SM, Walczak H. Linear ubiquitination: A newly discovered regulator of cell signalling. Trends Biochem Sci 2013;38:94-102.
29. Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z, Abhyankar A, Israël L, Trevejo-Nunez G, Bogunovic D, et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012;13: 1178-1186.
30. Chen BB, Coon TA, Glasser JR, McVerry BJ, Zhao J, Zhao Y, Zou C, Ellis B, Sciurba FC, Zhang Y, et al. A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation. Nat Immunol 2013;14:470-479.
31. Melino G, Gallagher E, Aqeilan RI, Knight R, Peschiaroli A, Rossi M, Scialpi F, Malatesta M, Zocchi L, Browne G, et al. Itch: A HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ 2008;15:1103-1112.
32. Perry WL, Hustad CM, Swing DA, O'Sullivan TN, Jenkins NA, Copeland NG. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat Genet 1998;18:143-146.
33. Lohr NJ, Molleston JP, Strauss KA, Torres-Martinez W, Sherman EA, Squires RH, Rider NL, Chikwava KR, Cummings OW, Morton DH, et al. Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Am J Hum Genet 2010;86:447-453.
34. Do-Umehara HC, Chen C, Urich D, Zhou L, Qiu J, Jang S, Zander A, Baker MA, Eilers M, Sporn PH, et al. Suppression of inflammation and acute lung injury by Miz1 via repression of C/EBP-d. Nat Immunol 2013;14:461-469.
35. Yang Y, Do H, Tian X, Zhang C, Liu X, Dada LA, Sznajder JI, Liu J. E3 ubiquitin ligase Mule ubiquitinates Miz1 and is required for TNFainduced JNK activation. Proc Natl Acad Sci USA 2010;107:13444- 13449.
36. Venuprasad K, Elly C, Gao M, Salek-Ardakani S, Harada Y, Luo JL, Yang C, Croft M, Inoue K, Karin M, et al. Convergence of Itchinduced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest 2006;116:1117-1126.
37. Oh SY, Park JU, Zheng T, Kim YK, Wu F, Cho SH, Barber D, Penninger J, Zhu Z. Cbl-b regulates airway mucosal tolerance to aeroallergen. Clin Exp Allergy 2011;41:434-442.
38. Collison A, Hatchwell L, Verrills N, Wark PA, de Siqueira AP, Tooze M, Carpenter H, Don AS, Morris JC, Zimmermann N, et al. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. Nat Med 2013; 19:232-237.
39. Carolan BJ, Heguy A, Harvey BG, Leopold PL, Ferris B, Crystal RG. Up-regulation of expression of the ubiquitin carboxyl-terminal hydrolase L1 gene in human airway epithelium of cigarette smokers. Cancer Res 2006;66:10729-10740.
40. van Rijt SH, Keller IE, John G, Kohse K, Yildirim AO, Eickelberg O, Meiners S. Acute cigarette smoke exposure impairs proteasome function in the lung. Am J Physiol Lung Cell Mol Physiol 2012;303: L814-L823.
41. Min T, Bodas M, Mazur S, Vij N. Critical role of proteostasis-imbalance in pathogenesis of COPD and severe emphysema. J Mol Med (Berl) 2011;89:577-593.
42. Adenuga D, Yao H, March TH, Seagrave J, Rahman I. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Respir Cell Mol Biol 2009;40:464-473.
43. Krämer OH. HDAC2: A critical factor in health and disease. Trends Pharmacol Sci 2009;30:647-655.
44. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352:1967-1976.
45. Vadász I, Weiss CH, Sznajder JI. Ubiquitination and proteolysis in acute lung injury. Chest 2012;141:763-771.
46. Bachmaier K, Toya S, Gao X, Triantafillou T, Garrean S, Park GY, Frey RS, Vogel S, Minshall R, Christman JW, et al. E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury. Nat Med 2007;13:920-926.
47. Zhao J, Wei J, Mialki RK, Mallampalli DF, Chen BB, Coon T, Zou C, Mallampalli RK, Zhao Y. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat Immunol 2012;13:651-658.
48. Debigaré R, Côté CH, Maltais F. Ubiquitination and proteolysis in limb and respiratory muscles of patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2010;7:84-90.
49. Files DC, D'Alessio FR, Johnston LF, Kesari P, Aggarwal NR, Garibaldi BT, Mock JR, Simmers JL, DeGorordo A, Murdoch J, et al. A critical role for muscle RING finger-1 in acute lung injury-associated skeletal muscle wasting. Am J Respir Crit Care Med 2012;185:825-834.
50. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and b-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008;8:438-449.
51. Fuchs SY, Spiegelman VS, Kumar KG. The many faces of b-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 2004;23:2028-2036.
52. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011;184:252-258.
53. Chen BB, Glasser JR, Coon TA, Mallampalli RK. FBXL2 is a ubiquitin E3 ligase subunit that triggers mitotic arrest. Cell Cycle 2011;10:3487- 3494.
54. Chen BB, Glasser JR, Coon TA, Mallampalli RK. F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitinmediated degradation of cyclin D3 resulting in cell cycle arrest. Oncogene 2012;31:2566-2579.
55. Chen BB, Glasser JR, Coon TA, Zou C, Miller HL, Fenton M, McDyer JF, Boyiadzis M, Mallampalli RK. F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. Blood 2012;119:3132-3141.
56. Hung WC, Tseng WL, Shiea J, Chang HC. Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett 2010;288:156-161.
57. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol 2004;22:4165-4173.
58. Yokoi S, Yasui K, Mori M, Iizasa T, Fujisawa T, Inazawa J. Amplification and overexpression of SKP2 are associated with metastasis of non- small-cell lung cancers to lymph nodes. Am J Pathol 2004;165:175-180.
59. Thomas AQ, Lane K, Phillips J, Prince M, Markin C, Speer M, Schwartz DA, Gaddipati R, Marney A, Johnson J, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002;165:1322-1328.
60. Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001;344:573-579.
61. Conkright JJ, Apsley KS, Martin EP, Ridsdale R, Rice WR, Na CL, Yang B, Weaver TE. Nedd4-2-mediated ubiquitination facilitates processing of surfactant protein-C. Am J Respir Cell Mol Biol 2010; 42:181-189.
62. Kotorashvili A, Russo SJ, Mulugeta S, Guttentag S, Beers MF. Anterograde transport of surfactant protein C proprotein to distal processing compartments requires PPDY-mediated association with Nedd4 ubiquitin ligases. J Biol Chem 2009;284:16667-16678.
63. Wang C, Gale M Jr, Keller BC, Huang H, Brown MS, Goldstein JL, Ye J. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005;18: 425-434.
64. Chen BB, Coon TA, Glasser JR, Mallampalli RK. Calmodulin antagonizes a calcium-activated SCF ubiquitin E3 ligase subunit, FBXL2, to regulate surfactant homeostasis.Mol Cell Biol 2011;31:1905-1920.
65. Zou C, Butler PL, Coon TA, Smith RM, Hammen G, Zhao Y, Chen BB, Mallampalli RK. LPS impairs phospholipid synthesis by triggering b-transducin repeat-containing protein (b-TrCP)-mediated polyubiquitination and degradation of the surfactant enzyme acyl-CoA: lysophosphatidylcholine acyltransferase I (LPCAT1). J Biol Chem 2011;286:2719-2727.
66. Kumar KGS, Krolewski JJ, Fuchs SY. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J Biol Chem 2004; 279:46614-46620.
67. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946-2955.
68. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010;15: 243-249.
69. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-736.
70. Ceccarelli DF, Tang X, Pelletier B, Orlicky S, Xie W, Plantevin V, Neculai D, Chou YC, Ogunjimi A, Al-Hakim A, et al. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell 2011;145:1075-1087.
71. Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh D-C, Hathaway N, Dimova N, Cuny GD, King RW. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 2010;18: 382-395.
72. Orlicky S, Tang X, Neduva V, Elowe N, Brown ED, Sicheri F, Tyers M. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol 2010;28:733-737.